AR039985A1 - Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima - Google Patents
Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultimaInfo
- Publication number
- AR039985A1 AR039985A1 ARP030101617A ARP030101617A AR039985A1 AR 039985 A1 AR039985 A1 AR 039985A1 AR P030101617 A ARP030101617 A AR P030101617A AR P030101617 A ARP030101617 A AR P030101617A AR 039985 A1 AR039985 A1 AR 039985A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- heteroaralkyl
- compound
- aralkyl
- hydrogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 9
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 9
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 9
- 125000003107 substituted aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- -1 pyrimidinone compound Chemical class 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37965802P | 2002-05-09 | 2002-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039985A1 true AR039985A1 (es) | 2005-03-09 |
Family
ID=29420548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101617A AR039985A1 (es) | 2002-05-09 | 2003-05-08 | Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7166595B2 (OSRAM) |
| EP (1) | EP1503993A4 (OSRAM) |
| JP (1) | JP2006508030A (OSRAM) |
| KR (1) | KR20050036911A (OSRAM) |
| CN (1) | CN100491358C (OSRAM) |
| AR (1) | AR039985A1 (OSRAM) |
| AU (1) | AU2003223786A1 (OSRAM) |
| BR (1) | BR0309892A2 (OSRAM) |
| CA (1) | CA2485148A1 (OSRAM) |
| IL (2) | IL165046A0 (OSRAM) |
| IS (1) | IS7520A (OSRAM) |
| MX (1) | MXPA04011074A (OSRAM) |
| MY (1) | MY140767A (OSRAM) |
| NO (1) | NO20045043L (OSRAM) |
| NZ (1) | NZ537076A (OSRAM) |
| PL (1) | PL373412A1 (OSRAM) |
| RU (1) | RU2004135554A (OSRAM) |
| TW (1) | TW200406387A (OSRAM) |
| WO (1) | WO2003094839A2 (OSRAM) |
| ZA (1) | ZA200409881B (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| US20050107404A1 (en) * | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| JP2005529076A (ja) * | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | キナゾリノンの合成 |
| US7214800B2 (en) * | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| CN100491358C (zh) * | 2002-05-09 | 2009-05-27 | 赛特凯恩蒂克公司 | 嘧啶酮类化合物、组合物及方法 |
| CA2483627A1 (en) * | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005536475A (ja) | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| US7041676B2 (en) | 2002-06-14 | 2006-05-09 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004034972A2 (en) * | 2002-09-30 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004078758A1 (en) * | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| JP2007510660A (ja) * | 2003-11-07 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| US7439254B2 (en) * | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1697331A4 (en) | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
| BRPI0508552A (pt) * | 2004-03-08 | 2007-08-14 | Wyeth Corp | moduladores de canal de ìon |
| RU2006138864A (ru) * | 2004-04-06 | 2008-05-20 | Чирон Корпорейшн (Us) | Ингибиторы митотического кинезина |
| DE602005008953D1 (de) | 2004-05-21 | 2008-09-25 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
| WO2006002236A1 (en) * | 2004-06-18 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer |
| US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| US7375102B2 (en) * | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| CA2574204A1 (en) * | 2004-07-22 | 2006-01-26 | Astrazeneca Ab | Fused pyrimidones useful in the treatment and the prevention of cancer |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| CA2575188A1 (en) | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| WO2006049835A2 (en) | 2004-10-19 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Indole and benzimidazole derivatives |
| WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
| TW200716102A (en) * | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| KR20090081020A (ko) | 2006-11-13 | 2009-07-27 | 노파르티스 아게 | Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물 |
| CA2674318A1 (en) | 2007-01-05 | 2008-07-17 | Novartis Ag | Cyclized derivatives as eg-5 inhibitors |
| EP2070932A1 (en) * | 2007-12-13 | 2009-06-17 | 4Sc Ag | Pyrazolotriazines |
| AR077628A1 (es) * | 2009-07-02 | 2011-09-14 | Sanofi Aventis | Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb) |
| PL2542084T3 (pl) * | 2010-03-04 | 2018-05-30 | Merck Sharp & Dohme Corp. | Inhibitory katecholo-O-metylotransferazy i ich zastosowanie w leczeniu zaburzeń psychotycznych |
| PH12012502370A1 (en) * | 2010-05-31 | 2013-02-11 | Council Scient Ind Res | Anti tubercular agents |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PL3052485T3 (pl) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Związki heterocykliczne i ich zastosowania |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9902712B2 (en) | 2013-12-19 | 2018-02-27 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
| CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RU2649141C2 (ru) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans |
| NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| EP3390400B1 (en) | 2015-12-16 | 2021-01-20 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| EA037162B1 (ru) | 2016-03-24 | 2021-02-12 | Бристол-Маерс Сквибб Компани | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US12378203B2 (en) | 2018-11-01 | 2025-08-05 | Ahammune Biosciences Private Limited | Imidazole compounds, process for the synthesis and uses thereof |
| CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
| CN113897631B (zh) * | 2021-10-24 | 2023-05-09 | 昆明学院 | 电化学合成吡啶-2-酮衍生物的方法 |
| CN118530185B (zh) * | 2024-07-25 | 2024-10-22 | 山东仁一生物科技有限责任公司 | 一种制备4-羟基-6-甲基嘧啶的方法 |
Family Cites Families (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053063A (OSRAM) * | 1963-05-18 | |||
| US3320124A (en) * | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
| BG16042A3 (bg) | 1968-11-12 | 1972-05-20 | Nans Ott | Метод за получаване на нови 2(1н)-хиназолинони |
| US3962244A (en) * | 1971-01-23 | 1976-06-08 | Hoechst Aktiengesellschaft | Benzene sulfonyl ureas |
| US3740442A (en) * | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
| US4011324A (en) * | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
| DE2747357A1 (de) * | 1977-10-21 | 1979-04-26 | Bayer Ag | Substituierte pyrimidinyl(thiono) (thiol)phosphor (phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide |
| US4281127A (en) * | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
| DE3177311D1 (de) * | 1980-08-30 | 1994-06-09 | Hoechst Ag | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung. |
| AU543928B2 (en) | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
| JPS5821669A (ja) * | 1981-07-30 | 1983-02-08 | Tetsuzo Kato | ２−（１−アシルアミノアルキル）−６−メチル−４（３ｈ）−ピリミジノンの製法 |
| JPS6019789A (ja) * | 1983-07-12 | 1985-01-31 | Kyorin Pharmaceut Co Ltd | イミダゾ〔１，５−ａ〕ピリミジン誘導体 |
| JPS6143191A (ja) * | 1984-08-07 | 1986-03-01 | Kyorin Pharmaceut Co Ltd | イミダゾ〔１，５−ａ〕ピリミジン誘導体 |
| GB8524663D0 (en) * | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| GB8530144D0 (en) * | 1985-12-06 | 1986-01-15 | Fujisawa Pharmaceutical Co | Imidazo(1,5-a)heterocyclic compounds |
| JPH0333118Y2 (OSRAM) | 1986-02-20 | 1991-07-12 | ||
| DE3609598A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| GB8607683D0 (en) * | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5187167A (en) * | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
| US4729996A (en) * | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
| DE3721855A1 (de) | 1987-03-12 | 1988-09-22 | Merck Patent Gmbh | Aminosaeurederivate |
| GB8707053D0 (en) * | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
| US4866084A (en) * | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
| US4808590A (en) * | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
| US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
| US4857530A (en) * | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
| EP0341990B1 (en) | 1988-05-10 | 1994-11-09 | Imperial Chemical Industries Plc | Cephalosporins, process for their preparation and pharmaceutical compositions |
| GB8820129D0 (en) | 1988-08-24 | 1988-09-28 | Schering Agrochemicals Ltd | Fungicides |
| GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| GB8827988D0 (en) * | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
| GB8829296D0 (en) * | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
| US4970226A (en) | 1989-10-03 | 1990-11-13 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents |
| US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
| WO1991011999A1 (en) | 1990-02-13 | 1991-08-22 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
| US5264439A (en) | 1990-02-13 | 1993-11-23 | Merck & Co., Inc. | Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element |
| ZA913730B (en) * | 1990-05-30 | 1992-02-26 | Ici Plc | Anti-tumor compounds |
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| JPH04147135A (ja) * | 1990-10-10 | 1992-05-20 | Konica Corp | 新規な写真用カプラー |
| JPH04147134A (ja) * | 1990-10-09 | 1992-05-20 | Konica Corp | 新規な写真用カプラー |
| GB9105771D0 (en) * | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
| US5162325A (en) | 1991-05-07 | 1992-11-10 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| JPH0649070A (ja) * | 1991-07-23 | 1994-02-22 | Kyorin Pharmaceut Co Ltd | イミダゾ［１，５−ａ］ピリミジン誘導体 |
| US5316906A (en) * | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| CA2079982A1 (en) | 1991-10-07 | 1993-04-08 | Stephen E. De Laszlo | Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists |
| GB9125515D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| US5204354A (en) * | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| WO1993018036A1 (en) | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Condensed indole derivatives as 5ht4-receptor antagonists |
| GB9205907D0 (en) * | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| AU4376893A (en) | 1992-05-19 | 1993-12-13 | Immunopharmaceutics, Inc. | Compounds that modulate endothelin activity |
| GB9220571D0 (en) | 1992-09-30 | 1992-11-11 | Ici Plc | Quinazoline derivatives |
| JPH06148835A (ja) | 1992-11-04 | 1994-05-27 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料およびその処理方法 |
| US5817662A (en) | 1992-11-09 | 1998-10-06 | Cell Therapeutics, Inc. | Substituted amino alkyl compounds |
| US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| AU6087894A (en) * | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
| AU6092794A (en) * | 1993-01-19 | 1994-08-15 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
| US5574057A (en) | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
| US5401745A (en) | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
| US5837703A (en) | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
| US5342944A (en) * | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
| EP0724573A1 (en) * | 1993-10-20 | 1996-08-07 | PHARMACIA & UPJOHN COMPANY | Pyrimidinones as antiarthritic and anti-inflammatories |
| US20020198326A1 (en) | 1993-11-12 | 2002-12-26 | Taizo Aoyama | Polyolefin resin composition |
| US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| CA2113229C (en) * | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
| WO1995019171A1 (en) * | 1994-01-14 | 1995-07-20 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| CA2183562A1 (en) * | 1994-02-18 | 1995-08-24 | J. Peter Klein | Intracellular signalling mediators |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US5801182A (en) * | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
| DE4413169C1 (de) * | 1994-04-15 | 1995-05-11 | Daimler Benz Ag | Schaltvorrichtung für ein Zahnräderwechselgetriebe |
| US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| JPH09165385A (ja) * | 1994-08-26 | 1997-06-24 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
| US5891879A (en) * | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
| IL110831A (en) | 1994-08-31 | 1998-12-27 | Hadasit Med Res Service | Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis |
| IL112125A (en) | 1994-12-22 | 1998-02-08 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US5753664A (en) * | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
| US6245768B1 (en) * | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| WO1996039403A1 (en) | 1995-06-05 | 1996-12-12 | Neurogen Corporation | 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JP3486752B2 (ja) * | 1995-08-30 | 2004-01-13 | 株式会社大塚製薬工場 | キナゾリン−４−オン誘導体の製造方法 |
| WO1997010221A1 (en) | 1995-09-15 | 1997-03-20 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
| US5783577A (en) * | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19615262A1 (de) * | 1996-04-18 | 1997-10-23 | Bayer Ag | Heteroverknüpfte Phenylglycinolamide |
| HUP9902148A3 (en) | 1996-05-15 | 2002-11-28 | Pfizer | Novel 2,3 disubstituted-4(3h)-quinazolinones |
| US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
| WO1998026664A1 (en) | 1996-12-17 | 1998-06-25 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| US5852024A (en) | 1997-02-11 | 1998-12-22 | Hadasit | Treatment and prevention of adhesions |
| US6028075A (en) | 1997-02-11 | 2000-02-22 | Pines; Mark | Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| DE69831446T2 (de) | 1997-06-09 | 2006-06-14 | Pfizer Prod Inc | Chinazolin-4-on AMPA Antagonisten |
| US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
| US6627755B1 (en) * | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
| WO1998058947A1 (en) | 1997-06-25 | 1998-12-30 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US5972929A (en) | 1997-08-21 | 1999-10-26 | Shiseido Co., Ltd. | Quinazolinone derivative, hair growth promoter and external composition for skin using the same |
| IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| WO1999034806A1 (en) * | 1998-01-08 | 1999-07-15 | The Regents Of The University Of California | KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA) |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| EP1073643B1 (en) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| EP1091960A1 (en) | 1998-06-29 | 2001-04-18 | The Regents Of The University Of California | Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents |
| WO2000007017A2 (en) | 1998-07-27 | 2000-02-10 | President And Fellows Of Harvard College | Method of high-throughput screening |
| GB9911071D0 (en) | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
| US6197488B1 (en) | 1999-07-21 | 2001-03-06 | Eastman Kodak Company | Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity |
| EP1216232B1 (en) | 1999-08-27 | 2006-10-11 | ChemoCentryx Inc | Heterocyclic compounds and methods for modulating cxcr3 function |
| US6156758A (en) | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| CA2385736C (en) * | 1999-09-16 | 2011-11-15 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CN102584799A (zh) * | 1999-09-16 | 2012-07-18 | 田边三菱制药株式会社 | 含氮的6-员芳香环化合物 |
| KR20020047185A (ko) | 1999-09-28 | 2002-06-21 | 플레믹 크리스티안 | 퀴나졸리논 |
| EP1216235A1 (en) | 1999-09-28 | 2002-06-26 | MERCK PATENT GmbH | Quinazolinones |
| EP1216242A1 (en) | 1999-10-01 | 2002-06-26 | Advanced Medicine, Inc. | Macrocyclic quinazolinones and their use as local anesthetics |
| EP1686120A3 (en) * | 1999-10-27 | 2007-05-30 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6380205B1 (en) * | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
| US6495561B2 (en) * | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US6291499B1 (en) | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
| US6369076B1 (en) | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| WO2001049287A1 (en) * | 1999-12-30 | 2001-07-12 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| ES2159488B1 (es) | 2000-03-07 | 2002-04-16 | Uriach & Cia Sa J | Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica. |
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| US7115653B2 (en) * | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| WO2001074344A2 (en) | 2000-03-30 | 2001-10-11 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US6613798B1 (en) * | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US6518277B1 (en) | 2000-04-25 | 2003-02-11 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| BR0111541A (pt) | 2000-06-09 | 2003-07-01 | Osi Pharm Inc | Formulações lipossÈmicas inibidoras de timidilato sintase de benzoquinazolina |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| EP1174430A1 (en) | 2000-07-20 | 2002-01-23 | Universität Konstanz | Process for the preparation of heterocycles by using C1-building blocks |
| JP2004504397A (ja) | 2000-07-26 | 2004-02-12 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 抗菌活性を有するアミノピペリジンキノリン類およびそれらのアザイソステリックアナログ類 |
| EP1307201B1 (de) | 2000-08-01 | 2004-11-24 | Bayer HealthCare AG | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
| MXPA03001306A (es) | 2000-08-11 | 2003-10-15 | Boehringer Ingelheim Pharma | Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina. |
| ES2623711T3 (es) | 2000-10-13 | 2017-07-12 | Curis, Inc. | Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos |
| US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AU2001297717B2 (en) | 2000-12-11 | 2006-02-23 | Amgen Inc. | CXCR3 antagonists |
| JP4178816B2 (ja) * | 2001-03-15 | 2008-11-12 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2004529918A (ja) * | 2001-04-09 | 2004-09-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物 |
| US7365199B2 (en) * | 2001-04-20 | 2008-04-29 | Fujifilm Corporation | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| US20030220338A1 (en) | 2001-07-16 | 2003-11-27 | Watkins Will J. | Fungal efflux pump inhibitors |
| AU2002322585A1 (en) * | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| EP2116248A1 (en) * | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
| CA2459584A1 (en) * | 2001-09-05 | 2003-03-13 | Cynthia C. Bamdad | Compositions and use thereof in the treatment of cancer |
| SI1441735T1 (sl) * | 2001-10-26 | 2006-06-30 | Angeletti P Ist Richerche Bio | N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze |
| AU2002334205B2 (en) * | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| WO2003039460A2 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003043961A2 (en) * | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
| US6753428B2 (en) * | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| CA2467726A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| ES2291543T3 (es) | 2001-12-06 | 2008-03-01 | MERCK & CO., INC. | Inhibicion de kinesina mitotica. |
| AU2002363960B2 (en) | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| US20050107404A1 (en) * | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| AU2002351183B2 (en) | 2001-12-06 | 2008-05-08 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| CA2443023A1 (en) | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| JP2005529076A (ja) | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | キナゾリノンの合成 |
| US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| ATE507210T1 (de) | 2002-03-07 | 2011-05-15 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| JP4399269B2 (ja) | 2002-03-08 | 2010-01-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
| WO2003084544A2 (en) | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| CN100491358C (zh) | 2002-05-09 | 2009-05-27 | 赛特凯恩蒂克公司 | 嘧啶酮类化合物、组合物及方法 |
| US7214800B2 (en) * | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| CA2483627A1 (en) | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005536475A (ja) * | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| EP1517904A4 (en) | 2002-05-23 | 2007-02-21 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| US7348440B2 (en) | 2002-06-14 | 2008-03-25 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7041676B2 (en) * | 2002-06-14 | 2006-05-09 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ATE356804T1 (de) | 2002-06-14 | 2007-04-15 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| WO2004004652A2 (en) | 2002-07-08 | 2004-01-15 | Merck & Co., Inc. | Mitotic kinesin binding site |
| WO2004006916A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| US20040092561A1 (en) * | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| AU2003263323A1 (en) | 2002-09-07 | 2004-03-29 | Celltech R And D Limited | Quinazolinone derivatives |
| WO2004034972A2 (en) | 2002-09-30 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004064741A2 (en) | 2003-01-17 | 2004-08-05 | Cytokinetics Inc. | Compounds, compositions, and methods |
| WO2004078758A1 (en) | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
-
2003
- 2003-05-02 CN CNB03816177XA patent/CN100491358C/zh not_active Expired - Fee Related
- 2003-05-02 NZ NZ537076A patent/NZ537076A/en unknown
- 2003-05-02 CA CA002485148A patent/CA2485148A1/en not_active Abandoned
- 2003-05-02 EP EP03719989A patent/EP1503993A4/en not_active Withdrawn
- 2003-05-02 RU RU2004135554/04A patent/RU2004135554A/ru unknown
- 2003-05-02 JP JP2004502928A patent/JP2006508030A/ja active Pending
- 2003-05-02 US US10/429,195 patent/US7166595B2/en not_active Expired - Fee Related
- 2003-05-02 BR BRPI0309892-3A patent/BR0309892A2/pt not_active IP Right Cessation
- 2003-05-02 AU AU2003223786A patent/AU2003223786A1/en not_active Abandoned
- 2003-05-02 KR KR1020047018077A patent/KR20050036911A/ko not_active Ceased
- 2003-05-02 WO PCT/US2003/013627 patent/WO2003094839A2/en not_active Ceased
- 2003-05-02 PL PL03373412A patent/PL373412A1/xx unknown
- 2003-05-02 MX MXPA04011074A patent/MXPA04011074A/es active IP Right Grant
- 2003-05-07 MY MYPI20031725A patent/MY140767A/en unknown
- 2003-05-07 TW TW092112382A patent/TW200406387A/zh unknown
- 2003-05-08 AR ARP030101617A patent/AR039985A1/es unknown
-
2004
- 2004-11-03 IS IS7520A patent/IS7520A/is unknown
- 2004-11-04 IL IL16504604A patent/IL165046A0/xx unknown
- 2004-11-19 NO NO20045043A patent/NO20045043L/no not_active Application Discontinuation
- 2004-12-07 ZA ZA200409881A patent/ZA200409881B/en unknown
-
2006
- 2006-11-15 US US11/600,683 patent/US7482343B2/en not_active Expired - Fee Related
-
2007
- 2007-11-20 IL IL187528A patent/IL187528A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY140767A (en) | 2010-01-15 |
| CN100491358C (zh) | 2009-05-27 |
| EP1503993A4 (en) | 2006-05-03 |
| ZA200409881B (en) | 2006-04-26 |
| CA2485148A1 (en) | 2003-11-20 |
| KR20050036911A (ko) | 2005-04-20 |
| US7166595B2 (en) | 2007-01-23 |
| US7482343B2 (en) | 2009-01-27 |
| WO2003094839A8 (en) | 2004-06-24 |
| IL187528A0 (en) | 2008-03-20 |
| JP2006508030A (ja) | 2006-03-09 |
| US20070135432A1 (en) | 2007-06-14 |
| NO20045043L (no) | 2005-02-08 |
| IL165046A0 (en) | 2005-12-18 |
| IS7520A (is) | 2004-11-03 |
| CN1665788A (zh) | 2005-09-07 |
| WO2003094839A3 (en) | 2004-09-16 |
| NZ537076A (en) | 2007-06-29 |
| BR0309892A2 (pt) | 2011-04-05 |
| PL373412A1 (en) | 2005-08-22 |
| RU2004135554A (ru) | 2006-01-20 |
| US20040077662A1 (en) | 2004-04-22 |
| AU2003223786A1 (en) | 2003-11-11 |
| EP1503993A2 (en) | 2005-02-09 |
| MXPA04011074A (es) | 2005-06-08 |
| TW200406387A (en) | 2004-05-01 |
| WO2003094839A2 (en) | 2003-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039985A1 (es) | Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima | |
| ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| CL2008002852A1 (es) | Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas. | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
| CL2012002381A1 (es) | Combinacion que comprende (2-hidroxietoxi)-amida del acido 6-(4-bromo-2- fluorofenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico o una sal del mismo y un agente anti-tumoral seleccionado de un grupo definido; uso para tratar un trastorno hiperproliferativo en un mamifero. | |
| SV2002000097A (es) | Inhibidores de metaloproteasas ref.pcs10322/82940 /bb | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| DE60305724D1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| AR035732A1 (es) | Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados | |
| ES2195785B1 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| CL2011000710A1 (es) | Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer. | |
| AR015940A1 (es) | Derivados de rapamicina que contiene tetrazol con vidas medias acortadas y su uso para la manufactura de un medicamento | |
| BR0113643A (pt) | Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos | |
| TW200626139A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| SV2003001148A (es) | Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv | |
| CO5180590A1 (es) | Derivados de camptotecina que tienen actividad anti tumores | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR045161A1 (es) | Derivados de quinazolina | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| UY28271A1 (es) | Compuestos químicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |